Intermountain Precision Genomics has announced a new precision oncology collaboration with Myriad Genetics, Inc. The partnership will create the world’s most comprehensive offering for cancer patients that will include both tumor-specific and hereditary analysis.
Through this collaborative effort, Intermountain’s Precision Genomics’ TheraMap panel will be offered with Myriad’s myChoice CDx and myRisk genetics tests. This will provide oncologists a complete genetic analysis for their patients in one, easy-to-interpret report. It will help physicians direct the most effective and individualized treatment options for each of their cancer patients.
Lincoln Nadauld, MD, PhD
Here’s an example of how the partnership will work. When an ovarian cancer patient goes to her oncologist, she will now receive both Myriad’s myChoice CDx and Precision Genomics’ TheraMap test. This streamlined test approach will sequence the DNA specific to her tumor and cancer type, helping the oncologist know which type of treatments will be the most successful for her individual case. The patient will also receive Myriad’s myRisk test to see if the cancer is hereditary and could possibly impact family members.
“As a physician, I’m excited to make this comprehensive offering available to more patients,” says Lincoln Nadauld, MD, PhD, oncologist and Intermountain’s vice president and chief of precision health and academics. “This partnership allows us to make a tremendous impact by providing the best that precision cancer care has to offer.”
The complete offering of tests will be available in the second half of 2021.